We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00477789
Recruitment Status : Completed
First Posted : May 24, 2007
Last Update Posted : May 24, 2007
Information provided by:
Universita di Verona

Brief Summary:
In patients with chronic heart failure (CHF)due to dilated cardiomyopathy diastolic dysfunction occurs frequently and is related to a poor outcome. We have previously shown that parameters of diastolic function significantly correlate with uric acid levels, a marker of impaired oxidative metabolism. We aimed to determine whether inhibition of xanthine oxidase with allopurinol might affect diastolic function in patients with CHF.

Condition or disease Intervention/treatment Phase
Chronic Heart Failure Drug: allopurinol Phase 4

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Primary Outcome Measures :
  1. diastolic function uric acid levels BNP [ Time Frame: three months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • chronic heart failure;
  • left ventricular systolic dysfunction (ejection fraction <45%)
  • stable clinical conditions in the previous three months
  • optimal medical therapy for CHF
  • normal sinus rhythm
  • written informed consent
  • age >18 years

Exclusion Criteria:

  • renal failure (s-creatinine >2.5 mg/dl)
  • already on allopurinol
  • malignancies
  • chronic inflammatory diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00477789

Division of Cardiology, University Hospital of Verona
Verona, Italy, 37129
Sponsors and Collaborators
Universita di Verona
Principal Investigator: Mariantonietta Cicoira, MD, PhD Division of Cardiology, University of Verona, Italy

ClinicalTrials.gov Identifier: NCT00477789     History of Changes
Other Study ID Numbers: 802
First Posted: May 24, 2007    Key Record Dates
Last Update Posted: May 24, 2007
Last Verified: May 2007

Keywords provided by Universita di Verona:
chronic heart failure
diastolic dysfunction
uric acid

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Free Radical Scavengers
Protective Agents
Physiological Effects of Drugs